Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 51, Issue 18, Pages 5780-5788Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm8006245
Keywords
-
Categories
Funding
- Ministry of Education, Culture, Sports, Science and Technology (MEXT)
- High-Tech Research Center Project for Private Universities
- National Institute of Biomedical Innovation (NIBIO)
Ask authors/readers for more resources
Previously, we designed and synthesized a potent NF-kappa B inhibitor, DHMEQ. Although DHMEQ showed potent anti-inflammatory and anticancer activities in animals, its molecular target has not been elucidated. In the present study, its target protein was found to be p65 and other Rel homology proteins. We found that (-)-DHMEQ bound to p65 covalently with a 1: 1 stoichiometry by conducting SPR and MALDI-TOF MS analyses. MS analysis of the chymotrypsin-digested peptide suggested the binding of (-)-DHMEQ to a Cys residue. Formation of Cys/(-)-DHMEQ adduct in the protein was supported by chemical synthesis of the adduct. Substitution of specific Cys in p65 and other Rel homology proteins resulted in the loss of (-)-DHMEQ binding. (-)-DHMEQ is the first NF-kappa B inhibitor that was proven to bind to the specific Cys by chemical methodology. These findings may explain the highly selective inhibition of NF-kappa B and the low toxic effect of (-)-DHMEQ in cells and animals.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available